Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
NCT07502339Phase 4Not yet recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of upadacitinib in ulcerative colitis (UC), sponsored by University of California, San Francisco. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07502339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502339.